Features | Partner Sites | Information | LinkXpress
Sign In
SEEGENE
RANDOX LABORATORIES
FOCUS DIAGNOSTICS, INC.

Blood-Based Biomarkers Validated for Mild Cognitive Impairment

By Labmedica International staff writers
Posted on 20 Jan 2014
Image: TaqMan Reverse Transcription Kit for microRNA (Photo courtesy of Life technologies).
Image: TaqMan Reverse Transcription Kit for microRNA (Photo courtesy of Life technologies).
A minimally invasive test is essential for the early detection and monitoring of Alzheimer's and other neurodegenerative diseases for both drug development and planning of patient care.

Plasma micro ribonucleic acid biomarkers have been used for the detection of mild cognitive impairment (MCI) which is a condition characteristic of early stages of many neurodegenerative diseases, including Alzheimer's disease.

Scientists from the molecular diagnostic company DiamiR, LLC, (Princeton, NJ, USA) working with colleagues from the Roskamp Institute (Sarasota, FL, USA) obtained plasma samples from 50 MCI patients and 50 age matched controls (AMC). The miRNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR) analysis were performed by Asuragen Inc. (Austin, TX, USA). Single target qRT-PCR was performed using the TaqMan Reverse Transcription Kit and miRNA specific stem-loop primers (Applied Biosystems; Foster City, CA, USA).

The investigators reported that two families of microRNA biomarkers, miR-132 and miR-134 families, detect MCI with the overall accuracy of 96% and 87% respectively, when plasma samples of MCI patients are compared to plasma samples of age/gender matched control subjects. The two families of biomarkers were identified among neurite/synapse enriched microRNAs and paired with brain-enriched microRNA normalizers using proprietary algorithms and software developed at DiamiR. The biomarkers are believed to reflect pathological processes underlying synaptic dysfunction and destruction characteristic of an early, preclinical stage of dementia development.

Samuil R. Umansky MD, PhD, DSc, president and chief scientific officer of DiamiR, said, “The results of this study are highly encouraging for the development of a test for early detection of Mild Cognitive Impairment, a condition affecting millions of Americans. The reported data validates DiamiR's innovative approach of using organ-enriched microRNAs for early detection of a pathology, when therapeutic interventions as well as life style changes are much more likely to have a meaningful positive impact.” The study was published on December 22, 2013, in the journal Aging.

Related Links:
DiamiR LLC
Roskamp Institute
Applied Biosystems


PURITAN MEDICAL
ADVANCED INSTRUMENTS
GREINER-BIO-ONE
BioConferenceLive

Channels

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Beckman Coulter and hc1.com Enter Strategic Partnership for Innovative Healthcare Cloud System

The diagnostics division of Beckman Coulter (Brea, CA, USA) and hc1.com (Indianapolis, IN, USA) have announced a partnership to bring an innovative healthcare cloud-technology system to clinical laboratories. The system, hc1.com's "Healthcare Relationship Cloud," helps turn large amounts of clinical data into actionable... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.